Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Roche Holding AG (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RHHBY
Over the counter
2834
https://www.roche.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Roche Holding AG (ADR)
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
- May 17th, 2024 2:04 pm
Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
- May 17th, 2024 10:43 am
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
- May 16th, 2024 6:31 pm
Roche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity
- May 16th, 2024 2:08 pm
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
- May 16th, 2024 1:44 pm
Stocks to Watch Thursday: Chubb, Deere, Baidu, Walmart, Under Armour
- May 16th, 2024 1:35 pm
Roche keeps pace in obesity drug field with early study data
- May 16th, 2024 12:07 pm
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
- May 16th, 2024 11:56 am
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
- May 16th, 2024 5:10 am
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
- May 16th, 2024 5:00 am
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- May 15th, 2024 5:00 am
Q1 2024 Lineage Cell Therapeutics Inc Earnings Call
- May 10th, 2024 6:09 pm
Phanes Therapeutics signs clinical supply agreement with Roche
- May 9th, 2024 8:42 am
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
- May 8th, 2024 7:10 pm
Q1 2024 Halozyme Therapeutics Inc Earnings Call
- May 8th, 2024 11:05 am
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
- May 2nd, 2024 3:13 pm
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
- May 2nd, 2024 1:42 pm
Q1 2024 Sarepta Therapeutics Inc Earnings Call
- May 2nd, 2024 10:01 am
The top pharmaceutical companies by R&D expenditure
- May 2nd, 2024 7:01 am
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
- May 1st, 2024 10:42 am
Scroll